Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
Oral Semaglutide Cut Heavy Drinking Days in a Phase 2 Trial. It Missed Its Primary Endpoint.
A new randomized trial found fewer heavy drinking days with oral semaglutide, but no significant benefit on its primary craving endpoint. The mixed result is the story.
A Peptide Spray Improved Diabetic Foot Infections. The Bacteria Told a More Complicated Story
A randomized trial found that topical peceleganan improved short-term clinical response in infected diabetic foot ulcers, while overall bacterial eradication remained uncertain.
CagriSema Beat High-Dose Semaglutide on HbA1c. The Margin Was Smaller Than the Headline
A 2,713-person phase 3 trial found CagriSema lowered HbA1c more than semaglutide 2.4 mg. The win was significant, but the average margin was 0.16 percentage points.
A Peptide Vaccine Made Humans Produce Antibodies Against IL-17A. That Is the Start, Not the Finish.
A 20-person Phase 1 trial found that FPP003 induced anti-IL-17A antibodies without severe or serious adverse events. Here is what that proves, and what it does not.
Can GLP-1 Drugs Slow Parkinson’s? The New Meta-Analysis Hides a Split Verdict
A positive 2026 meta-analysis clashes with a negative phase 3 trial and other reviews. Here is why the same GLP-1 evidence produces opposite Parkinson’s headlines.
DD01 Cut Liver Fat in 12 Weeks. Here's What the Phase 2 Trial Really Proved
In a randomized phase 2 trial, 76% of DD01 participants cut liver fat by at least 30% in 12 weeks. The efficacy signal was strong, but nausea and vomiting were common.
A Longer-Lasting Thymosin Beta-4 Repaired Heart-Attack Damage in Rats. Human Proof Is the Hard Part.
A new PEGylated thymosin beta-4 lasted four times longer and improved heart function after myocardial infarction in rats. The formulation is promising, but the human evidence is still mixed.
A Phase 3 Peptide Stroke Trial Failed. The Severe-Stroke Signal Is Hard to Ignore
A new phase 3 trial found no overall benefit from EGF plus GHRP-6 after ischemic stroke, but a small severe-stroke subgroup showed lower disability and mortality.
GLP-1 Drugs, Anxiety, and Depression: What the New Data Actually Says
A large real-world study just compared semaglutide and tirzepatide to older weight-loss drugs on mental health outcomes. The results split in an unexpected direction.
Amylin Therapies: The Next Generation of Weight-Loss Drugs Beyond GLP-1s
New clinical data from ADA 2026 and ECO 2026 shows amylin-based therapies delivering double-digit weight loss with better muscle preservation and fewer GI side effects than GLP-1s alone. Here's why every major pharma company is building an amylin program.
Survodutide Cuts Liver Fat by 63% and Visceral Fat by 34% — Why the Weight Loss Numbers Tell Only Half the Story
The SYNCHRONIZE-1 trial showed survodutide delivers 16.6% weight loss, but the real story is what happens to the fat you can't see — deep visceral and liver fat that drives cardiometabolic disease.